Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Completed · Not applicable

Conditions studied: Renal Cell Carcinoma, Kidney Cancer

In brief

In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).

Key facts

Study ID

NCT02687139

Run by

Johns Hopkins University

People needed

34

Starts

2015-10-01

Expected to finish

2019-04-01

Last updated by the study team

2020-04-29

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma
• Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment

You may not qualify if…

• History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)
• Administered a radioisotope within 5 physical half-lives prior to study enrollment
• Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))
• Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.